CN104059130A - 关于st2蛋白抑制剂多肽及其应用 - Google Patents
关于st2蛋白抑制剂多肽及其应用 Download PDFInfo
- Publication number
- CN104059130A CN104059130A CN201410293557.9A CN201410293557A CN104059130A CN 104059130 A CN104059130 A CN 104059130A CN 201410293557 A CN201410293557 A CN 201410293557A CN 104059130 A CN104059130 A CN 104059130A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- cell
- protein inhibitor
- uterus carcinoma
- uterine cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 41
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 title claims abstract description 40
- 239000012268 protein inhibitor Substances 0.000 title claims description 24
- 229940121649 protein inhibitor Drugs 0.000 title claims description 24
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000012991 uterine carcinoma Diseases 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 230000005012 migration Effects 0.000 abstract description 6
- 238000013508 migration Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract 4
- 206010046766 uterine cancer Diseases 0.000 abstract 4
- 241000699670 Mus sp. Species 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000012930 cell culture fluid Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- NAPNAGZWHQHZLG-ZLUOBGJFSA-N Asp-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)N NAPNAGZWHQHZLG-ZLUOBGJFSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000007190 Chlamydia Infections Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- HEPLXMBVMCXTBP-QWRGUYRKSA-N Cys-Phe-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O HEPLXMBVMCXTBP-QWRGUYRKSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XZUUUKNKNWVPHQ-JYJNAYRXSA-N Gln-Phe-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O XZUUUKNKNWVPHQ-JYJNAYRXSA-N 0.000 description 1
- 101000680096 Homo sapiens Transmembrane emp24 domain-containing protein 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- CANPXOLVTMKURR-WEDXCCLWSA-N Lys-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN CANPXOLVTMKURR-WEDXCCLWSA-N 0.000 description 1
- 241001347978 Major minor Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010036624 Prepuce redundant Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410293557.9A CN104059130B (zh) | 2014-06-27 | 2014-06-27 | 关于st2蛋白抑制剂多肽及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410293557.9A CN104059130B (zh) | 2014-06-27 | 2014-06-27 | 关于st2蛋白抑制剂多肽及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104059130A true CN104059130A (zh) | 2014-09-24 |
CN104059130B CN104059130B (zh) | 2016-08-24 |
Family
ID=51547088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410293557.9A Expired - Fee Related CN104059130B (zh) | 2014-06-27 | 2014-06-27 | 关于st2蛋白抑制剂多肽及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104059130B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349346A (zh) * | 2016-08-30 | 2017-01-25 | 苏州普罗达生物科技有限公司 | 蛋白激酶抑制剂多肽及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331111A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——t1/st2受体结合蛋白10.23和编码这种多肽的多核苷酸 |
WO2013173761A2 (en) * | 2012-05-18 | 2013-11-21 | Amgen Inc. | St2 antigen binding proteins |
-
2014
- 2014-06-27 CN CN201410293557.9A patent/CN104059130B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1331111A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——t1/st2受体结合蛋白10.23和编码这种多肽的多核苷酸 |
WO2013173761A2 (en) * | 2012-05-18 | 2013-11-21 | Amgen Inc. | St2 antigen binding proteins |
Non-Patent Citations (1)
Title |
---|
DA-PENG LU ET AL.: "Serum soluble ST2 is associated with ER-positive breast cancer", 《BMC CANCER》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349346A (zh) * | 2016-08-30 | 2017-01-25 | 苏州普罗达生物科技有限公司 | 蛋白激酶抑制剂多肽及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104059130B (zh) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103417953B (zh) | 重组灵芝免疫调节蛋白(rLZ-8)在制备治疗黑色素瘤药物中的应用 | |
CN102850443B (zh) | 整合素阻断剂多肽及其应用 | |
Wu et al. | Trichinella spiralis muscle larvae excretory/secretory products trigger apoptosis and S-phase arrest of the non-small-cell lung cancer line A549 | |
CN104059130A (zh) | 关于st2蛋白抑制剂多肽及其应用 | |
CN104017055B (zh) | 一种关于st2蛋白抑制剂多肽及其应用 | |
CN104017056B (zh) | St2蛋白抑制剂多肽及其应用 | |
CN104004056A (zh) | 一种关于Cyclin D蛋白抑制剂多肽及其应用 | |
CN104045690B (zh) | 生长抑素受体激动剂多肽及其应用 | |
KR20220123033A (ko) | 암 치료 방법 및 의약 | |
CN104017057A (zh) | 一种st2蛋白抑制剂多肽及其应用 | |
CN103948614B (zh) | 七叶皂苷及其盐的制药用途 | |
CN115501231B (zh) | 预防和/或治疗肝癌的联用药物组合物及其应用 | |
CN116650453B (zh) | 大黄素在制备治疗食管癌及食管癌放疗增敏药物中的应用 | |
CN109223801A (zh) | 一种新的胃癌肿瘤干细胞杀伤剂及其应用 | |
CN113768924B (zh) | 一种能抑制肿瘤细胞的组合物及其相关应用 | |
CN104045689B (zh) | 一种关于生长抑素受体激动剂多肽及其应用 | |
CN104004060B (zh) | Cyclin D蛋白抑制剂多肽及其应用 | |
CN104045691B (zh) | Npas2蛋白激动剂多肽及其应用 | |
CN102633668A (zh) | 化合物在转录因子失调相关疾病的治疗药物中的应用 | |
Ser et al. | IDDF2022-ABS-0236 Healing the GUT with probiotics: can probiotics help relieve allergic rhinitis? | |
CN104031122B (zh) | 有关Cyclin D蛋白抑制剂多肽及其应用 | |
CN104086630B (zh) | 一种生长抑素受体激动剂多肽及其应用 | |
CN104017051A (zh) | 一种CyclinD蛋白抑制剂多肽及其应用 | |
CN104004063A (zh) | 一种关于Npas2蛋白激动剂多肽及其应用 | |
CN104694520A (zh) | 一种水解纤维蛋白溶酶原多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Fangjie Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160612 Address after: 266214 Jimo Second People's Hospital of Jimo City, Shandong Province Applicant after: Wang Fangjie Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: SUZHOU PULUODA BIOLOGICAL SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171208 Address after: 046011 North One Ring Road No. 9, Changzhi City, Shanxi Patentee after: CHANGZHI WUT ENGINEERING TECHNOLOGY Research Institute Address before: 266214 Jimo Second People's Hospital of Jimo City, Shandong Province Patentee before: Wang Fangjie |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 |